PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsCapecitabine
Xeloda(capecitabine)
Capecitabine, Ecansya, Xeloda (capecitabine) is a small molecule pharmaceutical. Capecitabine was first approved as Xeloda on 1998-04-30. It is used to treat breast neoplasms and colorectal neoplasms in the USA. It has been approved in Europe to treat breast neoplasms, colonic neoplasms, colorectal neoplasms, and stomach neoplasms. The pharmaceutical is active against thymidylate synthase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Capecitabine, Xeloda (discontinued: Capecitabine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Capecitabine
Tradename
Company
Number
Date
Products
XELODACHEPLAPHARM ArzneimittelN-020896 RX1998-04-30
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
capecitabineANDA2025-08-20
capecitabine 150mgANDA2020-12-22
capecitabine 500mgANDA2020-12-26
capecitabine tablets, 150 mg capecitabine tablets, 500 mgExport only2019-04-21
xelodaNew Drug Application2025-01-10
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
colorectal neoplasms—D015179—
breast neoplasmsEFO_0003869D001943C50
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01B: Antimetabolites
— L01BC: Pyrimidine analogues, antineoplastic antimetabolites
— L01BC06: Capecitabine
HCPCS
Code
Description
J8520
Capecitabine, oral, 150 mg
J8521
Capecitabine, oral, 500 mg
Clinical
Clinical Trials
2562 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCapecitabine
INNcapecitabine
Description
Capecitabine is a carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers. It has a role as an antineoplastic agent, a prodrug and an antimetabolite. It is a carbamate ester, an organofluorine compound and a member of cytidines.
Classification
Small molecule
Drug classnucleoside antiviral or antineoplastic agents, cytarabine or azarabine derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F
Identifiers
PDB—
CAS-ID154361-50-9
RxCUI—
ChEMBL IDCHEMBL1773
ChEBI ID31348
PubChem CID60953
DrugBankDB01101
UNII ID6804DJ8Z9U (ChemIDplus, GSRS)
Target
Agency Approved
TYMS
TYMS
Organism
Homo sapiens
Gene name
TYMS
Gene synonyms
TS
NCBI Gene ID
7298
Protein name
thymidylate synthase
Protein synonyms
TSase
Uniprot ID
Q8WYK4
Mouse ortholog
Tyms (22171)
thymidylate synthase (P07607)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Xeloda – Roche
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Capecitabine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 44,037 documents
View more details
Safety
Black-box Warning
Black-box warning for: Capecitabine, Capecitabine 150mg, Capecitabine 500mg, Xeloda
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
95,035 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use